• Homoharringtonine and SARS-CoV-2: Study Analysis

  2026-08-09

  The reference study evaluates Homoharringtonine as a broad coronavirus replication inhibitor and combines in vitro, mouse, and early human evidence. Its central innovation is a proposed upper-respiratory-tract intervention based on protein-elongation inhibition, although the small, uncontrolled clinical cohorts require cautious interpretation and further validation.

• Uridine, Trisodium Salt for RNA Workflows

  2026-08-08

  Uridine, Trisodium Salt supports cell-based RNA metabolism studies and vascular assays while helping researchers control reagent solubility and nucleotide handling. Its most useful role in PRINT workflows is as a carefully characterized cellular input and assay variable—not as a direct substitute for UTP in in vitro transcription.

• Cucurbitacin I: A Causal Perturbation Playbook

  2026-08-07

  Cucurbitacin I (JSI-124) is more than a STAT3 pathway inhibitor: it is a useful causal probe when molecular, phenotypic, and multicellular assay layers are aligned. This article connects its oncology applications with design principles from human SAN-plexus assembloids while clearly separating methodological insight from unsupported cardiac claims.

• Brassinolide: Precision Tool for Plant Growth and Apoptosis

  2026-08-07

  Brassinolide (24-Epibrassinolide) stands out as a dual-function molecule, enabling high-performance plant growth modulation and targeted apoptosis studies in oncology and metabolic disease models. This guide delivers expert protocol enhancements, troubleshooting strategies, and actionable insights for maximizing assay reliability with APExBIO’s Brassinolide.

• Zolmitriptan: 5-HT1B Receptor Agonist in Migraine Research M

  2026-08-06

  Zolmitriptan empowers migraine and cluster headache research by targeting 5-HT1B, 5-HT1D, and 5-HT1F receptors with high purity and reproducibility. This article delivers actionable protocols, advanced applications, and troubleshooting strategies to optimize serotonin receptor pharmacology workflows.

• Palonosetron Hydrochloride: Beyond Antiemesis—Mechanistic Pr

  2026-08-06

  Discover how Palonosetron hydrochloride, a highly selective 5-HT3 receptor antagonist, redefines assay precision and translational research in oncology and transporter studies. This article explores mechanistic insights and advanced applications that go beyond current clinical paradigms.

• CDC42-YAP-mTOR Axis Governs Intestinal Stem Cell Fate Transi

  2026-08-05

  This study establishes that CDC42-driven apical-basal polarity in intestinal stem cells orchestrates the crucial balance between stem cell maintenance and transit amplifying cell expansion through a Hippo-YAP-EGF-mTOR signaling cascade. These mechanistic insights refine our understanding of epithelial renewal and offer new targets for gastrointestinal homeostasis research.

• Docosahexaenoic Acid (DHA): Applied Workflows for Neuroprote

  2026-08-05

  Docosahexaenoic Acid (DHA) is reshaping neuroprotection workflows by restoring lipid homeostasis and reducing postoperative cognitive dysfunction through targeted intervention. This article delivers actionable protocols, troubleshooting strategies, and highlights from spatial metabolomics, empowering researchers to leverage DHA’s unique properties in advanced bench setups.

• Mc-Val-Cit-PABC-PNP: Protocol Guidance for ADC Peptide Linke

  2026-08-04

  Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable ADC peptide linker intended for organic solvent-based antibody-drug conjugate synthesis, enabling controlled, lysosomal payload release. It is optimized for research workflows requiring high specificity in targeted drug delivery and is unsuitable for aqueous, diagnostic, or clinical applications.

• Perospirone Inhibits Kv1.5 Channels in Coronary Arterial Cel

  2026-08-04

  A recent study reveals that the atypical antipsychotic Perospirone (SM-9018 free base) directly inhibits vascular Kv1.5 potassium channels in coronary arterial smooth muscle, independent of its classical serotonergic and dopaminergic pathways. This off-target effect suggests new considerations for cardiovascular safety and expands its utility in translational neuropsychiatric and cardiovascular research models.

• (-)-Norepinephrine (+)-bitartrate in Cardiomyopathy Models

  2026-08-03

  (-)-Norepinephrine (+)-bitartrate stands as the benchmark compound for inducing reproducible animal models of cardiomyopathy and dissecting adrenergic receptor signaling. Leveraging APExBIO's rigorously validated formulation, researchers achieve consistent cardiovascular modulation, streamlined protocols, and robust troubleshooting support.

• Lamotrigine in CNS and Cardiac Models: Protocols and Pitfall

  2026-08-03

  Lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine) stands apart as a high-purity sodium channel blocker for advanced epilepsy and cardiac sodium current research. This article delivers practical protocols, troubleshooting insights, and the latest blood-brain barrier assay strategies to maximize reproducibility and translational value in preclinical studies.

• Phosphatase Inhibitor Cocktail: Precision in Phosphorylation

  2026-08-02

  The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) from APExBIO enables reliable protein phosphorylation preservation in demanding workflows, excelling where subtle dephosphorylation skews results. Its dual-tube system streamlines immunoblotting, kinase activity assays, and advanced phosphoproteomics, setting a new standard for reproducibility and sample integrity.

• Adefovir (C6629): Data-Driven Antiviral Solutions for HBV As

  2026-08-01

  This article delivers actionable, scenario-based guidance for using Adefovir (SKU C6629) in hepatitis B virus research. By addressing protocol optimization, data interpretation, and vendor selection, we demonstrate how Adefovir enhances experimental reliability and reproducibility for biomedical researchers. Evidence-based insights and practical parameters support confident assay design and troubleshooting.

• Ziprasidone Augmentation in Anxious Depression: Efficacy Ins

  2026-07-31

  This article analyzes a randomized, double-blind trial investigating ziprasidone augmentation of escitalopram (Lexapro) in patients with major depressive disorder, focusing on differences between anxious and nonanxious depression. The findings clarify the nuanced efficacy of this augmentation strategy and its implications for antidepressant and anxiolytic research.

15834 records 1/1056 page Next 12345 下5页 Last page